CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the third quarter ended September 30, 2019, and provided an update on recent corporate and clinical developments. “With the dosing of the first patient in our pivotal Phase 3 clinical trial of zilucoplan for the treatment of generalized myasthenia gravis (gMG), as well as zilucoplan’s selection as one of the first therapeutic candidates to be evaluated in a pioneering platform trial for amyotrophic lateral sclerosis (ALS) sponsored by the Sean M. Healey & AMG Center for ALS at Mass General, we’ve made significant progress in executing against our strategic

This content is restricted to site members. If you are an existing user, please log in. New users may register too.